Ascendis Pharma A (ASND) Receivables - Net (2016 - 2025)
Ascendis Pharma A (ASND) has disclosed Receivables - Net for 10 consecutive years, with $164.5 million as the latest value for Q4 2025.
- Quarterly Receivables - Net fell 7.41% to $164.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $164.5 million through Dec 2025, down 7.41% year-over-year, with the annual reading at $164.5 million for FY2025, 7.41% down from the prior year.
- Receivables - Net hit $164.5 million in Q4 2025 for Ascendis Pharma A, down from $177.7 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $177.7 million in Q4 2024 to a low of $2.5 million in Q4 2021.
- Historically, Receivables - Net has averaged $79.1 million across 5 years, with a median of $38.6 million in 2023.
- Biggest five-year swings in Receivables - Net: surged 445.44% in 2021 and later dropped 7.41% in 2025.
- Year by year, Receivables - Net stood at $2.5 million in 2021, then skyrocketed by 382.81% to $12.2 million in 2022, then surged by 217.65% to $38.6 million in 2023, then soared by 360.35% to $177.7 million in 2024, then fell by 7.41% to $164.5 million in 2025.
- Business Quant data shows Receivables - Net for ASND at $164.5 million in Q4 2025, $177.7 million in Q4 2024, and $38.6 million in Q4 2023.